Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	125
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	85
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	75
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	45
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	43
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	35
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	32
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	30
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	27
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	24
Hormones, microbes, and PrEP drugs in the female genital tract	23
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	22
Comorbidities and the right dose: antipsychotics	22
Guidance for interactions between antiseizure medications	20
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	19
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	19
Bioactivity descriptors for in vivo toxicity prediction: now and the future	18
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	17
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	17
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	17
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	16
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	16
Correction	15
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	14
A comprehensive review of the efficacy and safety of ertugliflozin	14

A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	13
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	13
Development and hepatotoxicity of rifamycin derivatives	13
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	13
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	12
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	12
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	12
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	12
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	12
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	12
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	12
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	12
Drug-drug interactions between psychotropic medications and oral contraceptives	11
Population pharmacokinetic–pharmacodynamic analysis of givinostat	11
Risk factors and prediction for DILI in clinical practice	11
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	11
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	11
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	11
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	11
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	10
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	10
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	10
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	10
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	10
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	10
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	10
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	9
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	9
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	9
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	9
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	9
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	9
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	9
Positioning the new drugs for migraine	9
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	9
PBPK models of the female reproductive tract: current and future analysis	9
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	9
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	9
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	9
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	8
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	8
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	8
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions	8
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	8
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	8
Overcoming barriers to machine learning applications in toxicity prediction	8
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	7
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	7

Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	7
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	7
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	7
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	7
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	7
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	7
Managing intoxications with nicotine-containing e-liquids	7
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	7
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	7
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	7
Drug interactions in people with HIV treated with antivirals for other viral illnesses	7
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	7
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	7
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	7
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	7
Drug–drug interactions in HIV-infected patients receiving chemotherapy	6
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	6
Psychedelics, psychiatry and pharmacokinetics - where are we now?	6
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	6
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?	6
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	6
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	6
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	6
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	6
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis	6
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	6
Genetic variation in organic cation transporters and considerations in drug development	6
DILI prediction in drug development: present and future	6
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	6
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	6
Interindividual variability in statin pharmacokinetics and effects of drug transporters	6
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	6
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation	6
A comparative study on the consistency of different decision support software systems from the perspective of potential drug–drug interactions in intensive care unit patients	6
Paternal exposure to antiseizure medications and offspring outcomes: a systematic review and meta-analysis of observational studies	5
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	5
Drug–drug interactions involving antipsychotics and antihypertensives	5
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	5
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy	5
Transporters and drug secretion into human breast milk	5
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	5
Cephalosporins with warfarin increase the risk of bleeding: myth or fact?	5
Benzodiazepines and clozapine co-prescription in clinical practice: a systematic review and expert recommendations	5
A novel in vivo approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis	5
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity	5
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	5
How can we better address the pharmacokinetics of antipsychotics in children and adolescents?	5
Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling	5
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	5
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	5
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	5
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	5
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	5
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	5
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety	5
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia	5
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	5
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	5
Individualizing doses of antiepileptic drugs	5
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	5
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond	5
Cannabidiol: metabolism and clinical efficacy in epileptic patients	5
Sex-gender differences in pharmacokinetics	4
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	4
Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus complex i	4
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	4
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	4
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	4
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	4
Improving on in-silico prediction of oral drug bioavailability	4
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	4
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	4
A critical review of methotrexate clinical interactions: role of transporters	4
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	4
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	4
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	4
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	4
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	4
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	4

Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial	4
Drug-drug interactions in patients living with HIV who undergo solid organ transplant	4
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events	4
Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques	4
Suboptimal concentrations of isavuconazole in critically ill patients treated for mold infections: a population pharmacokinetic analysis	4
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	4
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	3
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	3
Impact of pediatric continuous renal replacement therapy parameters on meropenem, piperacillin, and tazobactam pharmacokinetics: an in vitro model	3
Modeling drug-induced liver injury: current status and future prospects	3
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	3
Inositols in the ovaries: activities and potential therapeutic applications	3
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	3
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	3
Epigenetics is involved in the pleiotropic effects of statins	3
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	3
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	3
Comparison of ADMET profile between thiosemicarbazide and semicarbazide derivatives regarding anticancer properties	3
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review	3
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro	3
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting	3
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	3
What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?	3
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	3